Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression
Nando Reza Pratama, Ifan Ali Wafa, David Setyo Budi, et al.
Vaccines (2022) Vol. 10, Iss. 12, pp. 2180-2180
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputs
Darvin Scott Smith, Maarten J. Postma, David N. Fisman, et al.
Vaccine (2025) Vol. 51, pp. 126879-126879
Closed Access | Times Cited: 1
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
Leukemia (2023) Vol. 37, Iss. 6, pp. 1175-1185
Open Access | Times Cited: 33
Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies
Shangchen Song, Zachary J. Madewell, Ming‐Jin Liu, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 29
The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States
Michele Kohli, Michael Maschio, Keya Joshi, et al.
Journal of Medical Economics (2023) Vol. 26, Iss. 1, pp. 1532-1545
Open Access | Times Cited: 19
Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024
Guiling Zhou, Nina Dael, Stefan Verweij, et al.
European Respiratory Review (2025) Vol. 34, Iss. 175, pp. 240222-240222
Open Access
Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis
Obaidur Rahman, Taro Kamigaki, Moe Moe Thandar, et al.
BMJ Open (2023) Vol. 13, Iss. 12, pp. e076892-e076892
Open Access | Times Cited: 14
The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA autumn 2024 vaccines in the United Kingdom
Michele Kohli, Michael Maschio, Amy Lee, et al.
Journal of Medical Economics (2024) Vol. 27, Iss. 1, pp. 1359-1372
Open Access | Times Cited: 3
Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry
Pellegrino Musto, Jon Salmanton‐García, Nicola Sgherza, et al.
Hematological Oncology (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 9
Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases
Charalampos Papagoras, Nikoleta Zioga, Vasileios Papadopoulos, et al.
Clinical Rheumatology (2023) Vol. 42, Iss. 12, pp. 3375-3385
Open Access | Times Cited: 8
Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany
Keya Joshi, Stefan Scholz, Michael Maschio, et al.
Journal of Medical Economics (2023) Vol. 27, Iss. 1, pp. 39-50
Open Access | Times Cited: 8
Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France
Amy S. Lee, Benjamin Davido, Ekkehard Beck, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Fall 2023 vaccines in the United States
Michele Kohli, Michael Maschio, Kedar Joshi, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 5
Relative effectiveness and durability of booster doses of SARS-CoV-2 vaccines: A systematic review and meta-analysis
Di Liu, Yi-Wen Jiang, Shiyu Wang, et al.
The Innovation Medicine (2024) Vol. 2, Iss. 1, pp. 100051-100051
Open Access | Times Cited: 1
The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2024 vaccines in the United Kingdom
Michele Kohli, Michael Maschio, Amy Lee, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Comprehensive statistical analysis reveals significant benefits of COVID-19 vaccination in hospitalized patients: propensity score, covariate adjustment, and feature importance by permutation
Esther Moraes, Magda Carvalho Pires, Amanda Abrantes Abreu Costa, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Estimating vaccine effectiveness against COVID-19 using cause-specific sick leave as an indicator: a nationwide population-based cohort study, Norway, July 2021 – December 2022
Hinta Meijerink, Lamprini Veneti, Anja Bråthen Kristoffersen, et al.
BMC Public Health (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Clinical and Economic impact of updated Fall 2023 COVID-19 vaccines in the Immunocompromised Population in Canada
Amy S. Lee, Kavisha Jayasundara, Michele Kohli, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Factors Related to Severity, Hospitalization, and Mortality of COVID-19 Infection among Patients with Autoimmune Diseases
Alvina Widhani, Sukamto Koesnoe, Suzy Maria, et al.
Tropical Medicine and Infectious Disease (2023) Vol. 8, Iss. 4, pp. 227-227
Open Access | Times Cited: 2
Community Level Correlates of COVID-19 Booster Vaccine Hesitancy in the United States: A Cross-Sectional Analysis
Henry Krasner, Nicolette Harmon, Jeffrey J. Martin, et al.
Vaccines (2024) Vol. 12, Iss. 2, pp. 167-167
Open Access
Traditional and Social Media Usage Associated With COVID-19 Vaccine Uptake in Sapporo, Japan
Satoshi Sunohara, Toshiaki Asakura, Takashi Kimura, et al.
Asia Pacific Journal of Public Health (2024) Vol. 36, Iss. 4, pp. 358-365
Closed Access
Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France
Amy Lee, Benjamin Davido, Ekkehard Beck, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access
Intensive Care during the COVID-19 Pandemic
Ying Wang, Yuefei Jin, Haiyan Yang
Vaccines (2023) Vol. 11, Iss. 1, pp. 125-125
Open Access | Times Cited: 1
Effectiveness of SARS-CoV-2 Vaccines against Omicron Infection and Severe Events: A Systematic Review and Meta-Analysis of Test-Negative Design Studies
Shangchen Song, Zachary J. Madewell, Ming‐Jin Liu, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Computational Analysis of Antibody Binding Mechanisms to the Omicron RBD of SARS-CoV-2 Spike Protein: Identification of Epitopes and Hotspots for Developing Effective Therapeutic Strategies
Mohammed Alshahrani
(2023)
Open Access | Times Cited: 1
Case Report: Kinetics and durability of humoral and cellular response of SARS-CoV-2 messenger RNA vaccine in a lung and kidney transplant recipient
James P. Long, Mithil Soni, Pawel Muranski, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top